ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,700.30
-0.31%
S&P ASX All Technology
3,078.20
-0.47%
Brent Oil
83.95
2.22%
US Dollar vs AUD
1.51206
-0.01%
Bitcoin
67,111.35
0.71%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. PHAXIAM Therapeutics SA (PHXM)

  7. PHAXIAM Therapeutics SA (PHXM) News

PHXM

PHAXIAM Therapeutics (PHXM)

PHAXIAM Therapeutics SA
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PHXM
DateTimeSourceHeadlineSymbolCompany
11/03/202423:31Edgar (US Regulatory)Form 15F-12B - Securities registration termination of foreign private issuers [Section 12(b)]NASDAQ:PHXMPHAXIAM Therapeutics SA
11/03/202417:00GlobeNewswire Inc.PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock MarketNASDAQ:PHXMPHAXIAM Therapeutics SA
06/03/202416:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PHXMPHAXIAM Therapeutics SA
05/03/202408:28Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
05/03/202408:27Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
05/03/202408:25Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
05/03/202408:22Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
05/03/202408:14Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
05/03/202408:09Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PHXMPHAXIAM Therapeutics SA
21/02/202422:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
21/02/202408:05GlobeNewswire Inc.PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital MarketNASDAQ:PHXMPHAXIAM Therapeutics SA
20/01/202402:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
19/01/202408:05GlobeNewswire Inc.PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024NASDAQ:PHXMPHAXIAM Therapeutics SA
16/11/202323:41Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
15/11/202308:05GlobeNewswire Inc.PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023NASDAQ:PHXMPHAXIAM Therapeutics SA
26/10/202300:21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
25/10/202307:05GlobeNewswire Inc.PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureusNASDAQ:PHXMPHAXIAM Therapeutics SA
24/10/202307:05GlobeNewswire Inc.TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendationNASDAQ:PHXMPHAXIAM Therapeutics SA
11/10/202321:53Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
05/10/202322:32Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
27/09/202305:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
21/09/202322:42Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
18/09/202322:16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
15/09/202322:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
07/09/202323:33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
28/07/202306:21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
 Showing the most relevant articles for your search:NASDAQ:PHXM

Your Recent History

ASX
XAO
Australian SE All Ordina...
ASX
TLS
Telstra
ASX
NCM
Newcrest Mining
ASX
WPL
Woodside Petroleum
ASX
WOW
Woolworths
NYSE
MRK
Merck
SPI
SP500
S&P 500
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
MSFT
Microsoft
ASX
MQG
Macquarie
ASX
CSL
CSL
FX
GBPAUD
Sterling vs AUD
ASX
RIO
Rio Tinto
ASX
XFL
S&P ASX 50
ASX
NAB
National Australia Bank
FX
AUDCAD
AUD vs CAD
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved